Therapeutics Company Announces Promising Results From Pilot Program
Vivos Therapeutics Reveals Encouraging Outcomes from a 7-Month, Multi-Site Pilot Study of Its Innovative Provider-Based Marketing and Distribution Approach.
Disclaimer: This article is for informational purposes only and does not constitute an endorsement or commercial promotion of Vivos Therapeutics, Inc. or its products.
Real-time information is available daily at https://stockregion.net
On June 12, 2024, Vivos Therapeutics, Inc. (“Vivos” or the “Company”) announced promising results from a seven-month pilot program testing a new provider-based marketing and distribution model. Vivos Therapeutics specializes in developing and commercializing treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults. The pilot program's outcomes offer valuable insights into the efficacy and potential impact of this novel approach.
The New Marketing and Distribution Model
Vivos' innovative marketing and distribution strategy focuses on collaborative efforts with dentists and sleep treatment providers. The goal is to offer OSA patients a comprehensive range of evidence-based treatments, including Vivos' advanced proprietary FDA-cleared CARE oral medical devices, oral appliances, and complementary therapies. This model represents a shift towards an integrated, patient-centered approach to treating sleep-related breathing disorders. The pilot program took place over seven months in various locations, including seven dental offices and one ear, nose, and throat specialist office across several states. These sites were chosen to represent diverse patient demographics, thereby providing a broad perspective on the model’s applicability and effectiveness. In total, 99 patients participated in the study, comprising 76 adults and 23 children under the age of 12.
Among the 76 adults newly diagnosed with OSA, a notable 79% (60 out of 76) opted for Vivos’ oral appliance therapy as opposed to continuous positive airway pressure (CPAP) machines or choosing no treatment at all. Only 5% (4 out of 76) of patients declined all treatment options, while 16% (12 out of 76) considered CPAP before making a final decision. Notably, no patients in the pilot chose surgical or neurostimulation implant options. This high acceptance rate for Vivos' treatments underscores the appeal and potential success of their approach.
The pilot also included a smaller cohort of 23 pediatric patients with orofacial and developmental abnormalities, conditions often associated with sleep and breathing disorders. These children exhibited symptoms such as tongue ties, mouth breathing, malocclusion, and smaller jaws. They were evaluated and treated using Vivos orthodontic guided growth appliances and oral myofunctional therapy. The inclusion of pediatric patients highlights the versatility of Vivos' treatments across different age groups and conditions.
Insights from Investment Partners
Mike Skaff, Managing Director at Seneca Partners, which recently sponsored a $7.5 million investment in Vivos, expressed optimism about the results. He noted that the high patient acceptance rates across various price points and therapy options compared to CPAP machines were impressive. Skaff views these results as a compelling validation of Vivos' business model and anticipates higher revenue and gross profit opportunities from the new medical channel. Kirk Huntsman, Chairman and CEO of Vivos, echoed this sentiment. He emphasized the positive implications of the pilot program data for the company’s new marketing and distribution model. Huntsman highlighted that the results demonstrate the potential for this approach to improve patient outcomes and drive business growth.
Vivos' new model emphasizes a comprehensive treatment approach to OSA. By collaborating with a broad network of healthcare providers, Vivos aims to address the varied needs of OSA patients more effectively. Their proprietary CARE oral medical devices and adjunctive therapies are designed to provide a non-invasive alternative to traditional CPAP machines, making treatment more accessible and acceptable to patients.
The success of the pilot program provides the importance of evidence-based treatments in managing OSA. Vivos' focus on validated, scientifically-backed therapies ensures that patients receive effective care tailored to their specific needs. This approach not only improves patient outcomes but also fosters trust and credibility among healthcare providers and patients alike.
Future Prospects
The positive results of this pilot program pave the way for further expansion and refinement of Vivos' marketing and distribution model. As the company continues to collaborate with healthcare providers, there is potential for this model to be adopted more widely, benefiting a larger population of OSA patients. The company's commitment to innovation and patient-centered care positions it well for future growth and success.
The seven-month pilot program conducted by Vivos Therapeutics offers valuable insights into the potential of their new provider-based marketing and distribution model. With high acceptance rates among both adult and pediatric patients, the model shows promise in improving patient outcomes and driving business growth. As Vivos continues to refine and expand this approach, it stands to make a significant impact on the treatment of sleep-related breathing disorders.
Disclaimer: This article is for informational purposes only and does not constitute an endorsement or commercial promotion of Vivos Therapeutics, Inc. or its products.
Real-time information is available daily at https://stockregion.net